Catalent (NYSE:CTLT) had its target price raised by research analysts at Royal Bank of Canada from $78.00 to $86.00 in a report released on Tuesday, The Fly reports. The brokerage presently has an “outperform” rating on the stock. Royal Bank of Canada’s price objective would suggest a potential upside of 11.62% from the stock’s current price.
Other analysts have also issued research reports about the stock. Zacks Investment Research lowered shares of Catalent from a “buy” rating to a “hold” rating in a research note on Friday, June 5th. Morgan Stanley lifted their price objective on shares of Catalent from $57.00 to $75.00 and gave the company an “overweight” rating in a research note on Wednesday, May 6th. Robert W. Baird lifted their price objective on shares of Catalent from $74.00 to $80.00 and gave the company an “outperform” rating in a research note on Friday, June 26th. Argus initiated coverage on shares of Catalent in a research note on Thursday, June 25th. They issued a “buy” rating for the company. Finally, Deutsche Bank lifted their price objective on shares of Catalent from $59.00 to $62.00 and gave the company a “hold” rating in a research note on Wednesday, May 6th. Three equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $77.71.
Catalent stock traded down $0.42 during mid-day trading on Tuesday, hitting $77.05. 149,748 shares of the stock were exchanged, compared to its average volume of 1,385,807. The company has a quick ratio of 1.58, a current ratio of 1.90 and a debt-to-equity ratio of 1.34. Catalent has a 12 month low of $31.04 and a 12 month high of $80.53. The firm’s fifty day simple moving average is $74.16 and its two-hundred day simple moving average is $61.96. The stock has a market capitalization of $12.00 billion, a price-to-earnings ratio of 109.76, a PEG ratio of 4.18 and a beta of 1.63.
In other Catalent news, SVP Scott Gunther sold 2,824 shares of Catalent stock in a transaction on Monday, June 29th. The shares were sold at an average price of $72.00, for a total transaction of $203,328.00. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Aristippos Gennadios sold 8,325 shares of Catalent stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $73.00, for a total transaction of $607,725.00. The disclosure for this sale can be found here. Company insiders own 1.30% of the company’s stock.
Institutional investors and hedge funds have recently bought and sold shares of the business. Stephenson National Bank & Trust purchased a new position in Catalent during the 1st quarter worth $42,000. FDx Advisors Inc. raised its stake in shares of Catalent by 390.1% during the 1st quarter. FDx Advisors Inc. now owns 35,318 shares of the company’s stock worth $48,000 after purchasing an additional 28,112 shares during the period. Shine Investment Advisory Services Inc. raised its stake in shares of Catalent by 205.0% during the 1st quarter. Shine Investment Advisory Services Inc. now owns 2,019 shares of the company’s stock worth $105,000 after purchasing an additional 1,357 shares during the period. Livforsakringsbolaget Skandia Omsesidigt bought a new stake in Catalent in the 2nd quarter valued at about $125,000. Finally, Pendal Group Ltd raised its stake in Catalent by 47.6% in the 1st quarter. Pendal Group Ltd now owns 2,421 shares of the company’s stock valued at $126,000 after acquiring an additional 781 shares during the period.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
Read More: What is a resistance level?
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.